<DOC>
	<DOCNO>NCT01943006</DOCNO>
	<brief_summary>Patients receive nutritional emulsion least 3 day treat Hirudoid cream placebo cream prevent treat phlebitis cause infusion . The treatment continue end infusion least 7 day . Number patient develop superficial phlebitis duration phlebitis record .</brief_summary>
	<brief_title>Efficacy Tolerability Hirudoid Cream Prophylaxis Treatment Infusion Phlebitis</brief_title>
	<detailed_description />
	<mesh_term>Thrombophlebitis</mesh_term>
	<mesh_term>Phlebitis</mesh_term>
	<mesh_term>Heparinoids</mesh_term>
	<criteria>Patients admit hospital require receive infusion complete nutritional emulsion 3 day ( KabivenÂ® Peripheral , 1400 kcal , 1920 ml , 750 mosmol/L , pH 5.6 ) , Aged 1865 year . Patients able understand requirement study agree sign inform consent , approve Independent Ethic Committee ( IEC ) /Institutional Review Board ( IRB ) , prior study . Patients know allergic Hirudoid ingredient Hirudoid Patients impaired skin integrity cause lesion soft tissue trauma Patients skin lesion ulceration severe dermatologic disease Patients receive complete nutritional emulsion infusion within 7 day inclusion Patients severe uncontrolled medical condition , make undesirable unsafe patient participate study , : Acute chronic uncontrolled severe infection , Unstable angina pectoris , symptomatic congestive heart failure , myocardial infarction , serious uncontrolled cardiac arrhythmia clinically serious cardiac disease , Uncontrolled diabetes define fast serum glucose &gt; 1.5 x ULN ; optimal glycaemic control achieve start trial therapy , Uncontrolled bleeding Patients know coagulation disorder Haemophilia , Thrombocytopenia , Thrombosis , Other severe hematologic condition like leukaemia , especially abnormal coagulation Patients symptom microangiopathy ( small vessel disease ) neuropathy relate diabetes diseases Patients hyperthyroidism hypothyroidism Patients pregnant breast feeding Patients anticoagulant therapy ( last 2 week ) Patients severe psychiatric condition Patients unable bear legal responsibility unable understand study Patients unreliable unable comply protocol , like alcohol drug abuser Patients participate another clinical trial past 12 week Patient relative , staff directly reporting , investigator Patient employee sponsor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Mucopolysaccaride polysulfate ( MPS )</keyword>
	<keyword>MPS</keyword>
	<keyword>Heparinoide</keyword>
	<keyword>Infusionphlebitis</keyword>
	<keyword>Prevention</keyword>
	<keyword>Superficial thrombophlebitis</keyword>
	<keyword>Treatment</keyword>
</DOC>